These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Delavirdine (Rescriptor) approved.
    Author: James JS.
    Journal: AIDS Treat News; 1997 Apr 18; (No 269):1-3. PubMed ID: 11364252.
    Abstract:
    The Food and Drug Administration (FDA) approved delavirdine (Rescriptor) for HIV-1 treatment in March. Delavirdine becomes the second non-nucleoside reverse transcriptase inhibitor approved; the first was nevirapine. The drug must be used in antiretroviral combinations because of resistance problems associated with using it alone. Delavirdine's primary side effect is skin rash, occasionally severe enough to cause permanent discontinuation of the treatment. The approval follows weak clinical data; further clinical testing is called for. Cost is relatively low at $2,250 annually.
    [Abstract] [Full Text] [Related] [New Search]